2016 Annual Meeting

Association for Molecular Pathology

Room CC Ballroom 6 E, March 13 2016, 7:30pm to 10:30pm


Association for Molecular Pathology

Implementing Molecular Testing to Make Treatment Decisions

Sunday, March 13, 2016
7:30 PM 10:30 PM
CC Ballroom 6 E

Moderators: Eric Duncavage, MD, Washington University School of Medicine St. Louis, MO
James R. Cook, MD, PhD, Cleveland Clinic, Cleveland, OH

Course Description:
In order to fully realize the goals of precision medicine in cancer, accurate methods are needed to gauge treatment response and monitor for cancer recurrence and progression. In the last several years next generation sequencing (NGS) approaches have provided us with an unprecedented view of cancer genomics and have identified several key genes involved in cancer pathogenesis. Clinical sequencing-based ‘cancer gene panels’ are now being adopted in the routine evaluation of many cancer types. While such panels can be used to identify therapeutic targets and stratify risk when performed on the initial primary tumor, sequencing across serial time points can provide additional prognostic information, and may be used to monitor cancer patients over time to determine the efficacy of a particular treatment and the extent to which a tumor is cleared. This companion meeting will focus on recent advances and future applications for the use of sequencing-based technologies to monitor tumor burden in hematologic malignancies and solid tumors.

Upon completion of this educational activity, participants should be better able to:

  1. Identify key methodological approaches and challenges in sequencing-based tumor burden monitoring.
  2. Compare the major advantages of multi time point tumor burden monitoring over current single time point ‘cancer panels’ to predict patient outcome.
  3. Describe how tumor burden monitoring is now being applied in the research setting and the impact of incomplete molecular disease clearance in leukemia.
  4. Recognize new concepts and challenges in solid tumor monitoring including cell free DNA and ‘liquid biopsy’ applications.


7:30 PM

New Insights into Molecular Monitoring in Cancer
Eric J. Duncavage, MD, Washington University School of Medicine, St. Louis, MO

7:45 PM

Molecular Monitoring in AML Can Inform Prognosis
Jeffery M. Klco, MD, PhD, St. Jude Children’s Research Hospital, St. Louis, MO

8:20 PM

Clinical Application of NGS for MRD Monitoring in Lymphoid Neoplasms
David Wu, MD, PhD, University of Washington, Seattle, WA

8:55 PM

Cell-free Tumor DNA for Cancer Monitoring
Christina Lockwood, PhD, DABCC, FACB, University of Washington, Seattle, WA

9:30 PM

Summary Overview
James Cook, MD, PhD, Cleveland Clinic, Cleveland, OH

10:00 PM

Questions and Answers


view more